Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1813925
PUBLISHER: Grand View Research | PRODUCT CODE: 1813925
Middle East & Africa Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report By Sample (Blood, Saliva) By Product (Reagents & Kits, Consumables), By Biomarker, By Diseases, By End-use, By Country, And Segment Forecasts, 2025 - 2033
PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Market Size & Trends:
The Middle East and Africa biomarker-based immunoassays market size was estimated at USD 165.4 million in 2024 and is projected to reach USD 234.2 million by 2033, growing at a CAGR of 3.8% from 2025 to 2033. The market growth is fueled by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools. Increasing demand for personalized medicine has driven clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring. Countries like Saudi Arabia, the UAE, and South Africa are at the forefront, investing heavily in diagnostic infrastructure and adopting international best practices.
A key trend shaping the market is the growing collaboration between global diagnostic leaders and regional healthcare providers. For instance, in January 2025, Diatech Pharmacogenetics expanded its collaboration with Merck to extend access to RAS biomarker testing for colorectal cancer patients in MEA, underscoring the region's rising focus on personalized cancer care. Such partnerships not only expand the availability of advanced biomarker assays but also accelerate technology transfer and capacity building across the region. This trend indicates that international companies view MEA as a critical growth frontier for precision diagnostics.
The MEA region offers untapped potential for biomarker-based immunoassays due to its expanding healthcare infrastructure and growing demand for precision medicine. Governments across Saudi Arabia, the UAE, and South Africa are investing heavily in advanced diagnostics to reduce dependence on overseas testing, which creates a strong opening for localized manufacturing and technology transfer. In addition, the rising prevalence of lifestyle-related diseases, combined with an increasing focus on early detection and personalized treatment, is driving adoption of biomarker assays in oncology, cardiology, and neurology. The growing emphasis on value-based care also positions biomarker testing as a cost-efficient solution, supporting earlier interventions and better patient outcomes.
Strategic collaborations are playing a critical role in shaping the MEA biomarker ecosystem. In 2025, Diatech Pharmacogenetics expanded its partnership with Merck to improve colorectal cancer care in the region through RAS biomarker testing, highlighting the momentum in companion diagnostics. Similarly, partnerships between diagnostic technology providers like IBL International and Grifols are advancing biomarker panels that could see uptake in MEA's expanding clinical research networks. Meanwhile, local institutions, such as King Faisal Specialist Hospital in Saudi Arabia, are launching advanced biomarker testing programs that integrate with global standards, underscoring the region's commitment to becoming a hub for innovation in precision diagnostics.
MEA Biomarker-based Immunoassays Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Middle East & Africa biomarker-based immunoassays market report based on the sample, product, biomarkers, diseases, end-use, and country.
- Sample Outlook (Revenue, USD Million, 2021 - 2033)
- Blood
- Tissue
- Urine
- Saliva
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Consumables
- Instruments/Analyzers
- Reagent & Kits
- Services
- Biomarker Outlook (Revenue, USD Million, 2021 - 2033)
- Safety & toxicity biomarkers
- Efficacy & Pharmacodynamic Biomarkers
- Predictive & Prognostic Biomarkers
- Surrogate/Exploratory Biomarkers
- Diseases Outlook (Revenue, USD Million, 2021 - 2033)
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
- End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Clinics
- Diagnostic Laboratories
- Research & Academic Institutes
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Product Code: GVR-4-68040-724-8
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Sample Segment
- 1.2.2. Product Segment
- 1.2.3. Biomarker Segment
- 1.2.4. Diseases Segment
- 1.2.5. End-use Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Biomarkerl
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. MEA Biomarker-Based Immunoassays Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising demand for precision medicine and personalized therapies
- 3.2.1.2. Increasing prevalence of chronic and infectious diseases
- 3.2.1.3. Technological advancements in immunoassay platforms
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost of advanced biomarker assays and platforms
- 3.2.1. Market driver analysis
- 3.3. MEA Biomarker-Based Immunoassays Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
Chapter 4. MEA Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. MEA Biomarker-Based Immunoassays Market Sample Movement Analysis
- 4.3. MEA Biomarker-Based Immunoassays Market Size & Trend Analysis, by sample, 2018 to 2030 (USD Million)
- 4.4. Blood
- 4.4.1. Blood market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.5. Tissue
- 4.5.1. Tissue market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6. Saliva
- 4.6.1. Saliva market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.7. Urine
- 4.7.1. Urine market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. MEA Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. MEA Biomarker-Based Immunoassays Market Product Movement Analysis
- 5.3. MEA Biomarker-Based Immunoassays Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
- 5.4. Consumables
- 5.4.1. Consumables market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.5. Instruments/Analyzers
- 5.5.1. Instruments/Analyzers market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.6. Reagent & Kits
- 5.6.1. Reagent & kits market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.7. Services
- 5.7.1. Services market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. MEA Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. MEA Biomarker-Based Immunoassays Market Biomarker Movement Analysis
- 6.3. MEA Biomarker-Based Immunoassays Market Size & Trend Analysis, by biomarkers, 2021 to 2033 (USD Million)
- 6.4. Safety & toxicity biomarkers
- 6.4.1. Safety & toxicity biomarkers market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.5. Efficacy & Pharmacodynamic Biomarkers
- 6.5.1. Efficacy & Pharmacodynamic Biomarkers market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.6. Predictive & Prognostic Biomarkers
- 6.6.1. Predictive & prognostic biomarkers market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.7. Surrogate/Exploratory Biomarkers
- 6.7.1. Surrogate/exploratory biomarkers market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7. MEA Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. MEA Biomarker-Based Immunoassays Market Diseases Movement Analysis
- 7.2.1. MEA Biomarker-Based Immunoassays Market Size & Trend Analysis, by diseases, 2021 to 2033 (USD Million)
- 7.3. Cancer
- 7.3.1. Cancer market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.4. Cardiovascular Diseases
- 7.4.1. Cardiovascular diseases market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.5. Neurological Diseases
- 7.5.1. Neurological diseases market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.6. Immunological Diseases
- 7.6.1. Immunological diseases testing market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.7. Others
- 7.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 8. MEA Biomarker-Based Immunoassays Market: End-use Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. MEA Biomarker-Based Immunoassays Market End-use Movement Analysis
- 8.2.1. MEA Biomarker-Based Immunoassays Market Size & Trend Analysis, by End-use, 2021 to 2033 (USD Million)
- 8.3. Hospitals & Clinics
- 8.3.1. Hospitals and clinics market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.4. Diagnostic Laboratories
- 8.4.1. Diagnostic Laboratories market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5. Research & Academic Institutes
- 8.5.1. Research & Academic Institutes market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6. Others
- 8.6.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 9. MEA Biomarker-Based Immunoassays Market: Regional Estimates & Trend Analysis
- 9.1. Regional Dashboard
- 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033
- 9.3. MEA
- 9.3.1. South Africa
- 9.3.1.1. Key country dynamics
- 9.3.1.2. Regulatory framework/ reimbursement structure
- 9.3.1.3. Competitive scenario
- 9.3.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.3.2. Saudi Arabia
- 9.3.2.1. Key country dynamics
- 9.3.2.2. Regulatory framework/ reimbursement structure
- 9.3.2.3. Competitive scenario
- 9.3.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.3.3. UAE
- 9.3.3.1. Key country dynamics
- 9.3.3.2. Regulatory framework/ reimbursement structure
- 9.3.3.3. Competitive scenario
- 9.3.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.3.4. Kuwait
- 9.3.4.1. Key country dynamics
- 9.3.4.2. Regulatory framework/ reimbursement structure
- 9.3.4.3. Competitive scenario
- 9.3.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.3.1. South Africa
Chapter 10. Competitive Landscape
- 10.1. Company/Competition Categorization
- 10.2. Strategy Mapping
- 10.3. Company Market Share Analysis, 2024
- 10.4. List of Key Certification Providers/Scheme Owners
- 10.5. Company Profiles/Listing
- 10.5.1. F. Hoffmann-La Roche AG
- 10.5.1.1. Company overview
- 10.5.1.2. Financial performance
- 10.5.1.3. Product benchmarking
- 10.5.1.4. Strategic initiatives
- 10.5.2. Abbott
- 10.5.2.1. Company overview
- 10.5.2.2. Financial performance
- 10.5.2.3. Product benchmarking
- 10.5.2.4. Strategic initiatives
- 10.5.3. Thermo Fisher Scientific Inc
- 10.5.3.1. Company overview
- 10.5.3.2. Financial performance
- 10.5.3.3. Product benchmarking
- 10.5.3.4. Strategic initiatives
- 10.5.4. Eurofins Scientific
- 10.5.4.1. Company overview
- 10.5.4.2. Financial performance
- 10.5.4.3. Product benchmarking
- 10.5.4.4. Strategic initiatives
- 10.5.5. QIAGEN
- 10.5.5.1. Company overview
- 10.5.5.2. Financial performance
- 10.5.5.3. Product benchmarking
- 10.5.5.4. Strategic initiatives
- 10.5.6. Bio-Rad Laboratories, Inc.
- 10.5.6.1. Company overview
- 10.5.6.2. Financial performance
- 10.5.6.3. Product benchmarking
- 10.5.6.4. Strategic initiatives
- 10.5.7. Siemens Healthineers AG
- 10.5.7.1. Company overview
- 10.5.7.2. Financial performance
- 10.5.7.3. Product benchmarking
- 10.5.7.4. Strategic initiatives
- 10.5.8. Merck KGaA
- 10.5.8.1. Company overview
- 10.5.8.2. Financial performance
- 10.5.8.3. Product benchmarking
- 10.5.8.4. Strategic initiatives
- 10.5.9. PerkinElmer Inc.
- 10.5.9.1. Company overview
- 10.5.9.2. Financial performance
- 10.5.9.3. Product benchmarking
- 10.5.9.4. Strategic initiatives
- 10.5.10. Agilent Technologies, Inc.
- 10.5.10.1. Company overview
- 10.5.10.2. Financial performance
- 10.5.10.3. Product benchmarking
- 10.5.10.4. Strategic initiatives
- 10.5.1. F. Hoffmann-La Roche AG
Product Code: GVR-4-68040-724-8
List of Tables
- Table 1 MEA biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
- Table 2 MEA biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 3 MEA biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 4 MEA biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 5 MEA biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 6 MEA biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 7 South Africa biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 8 South Africa biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 9 South Africa biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 10 South Africa biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 11 South Africa biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 12 Saudi Arabia biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 13 Saudi Arabia biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 14 Saudi Arabia biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 15 Saudi Arabia biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 16 Saudi Arabia biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 17 UAE biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 18 UAE biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 19 UAE biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 20 UAE biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 21 MEA biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 22 Kuwait biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 23 Kuwait biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 24 Kuwait biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 25 Kuwait biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 26 Kuwait biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 MEA biomarker-based immunoassays market segmentation
- Fig. 2 Data analysis biomarkers
- Fig. 3 Market formulation and validation
- Fig. 4 Data validating & publishing
- Fig. 5 Market research process
- Fig. 6 Information procurement
- Fig. 7 Primary research
- Fig. 8 Value-chain-based sizing & forecasting
- Fig. 9 QFD biomarker modelling for market share assessment
- Fig. 10 Market formulation & validation
- Fig. 11 Commodity flow analysis
- Fig. 12 Market outlook
- Fig. 13 Segment snapshot-1
- Fig. 14 Segment snapshot-2
- Fig. 15 Competitive landscape snapshot
- Fig. 16 Market trends & outlook
- Fig. 17 Porter's five force analysis
- Fig. 18 PESTEL analysis
- Fig. 19 MEA biomarker-based immunoassays market: Sample outlook key takeaways
- Fig. 20 MEA biomarker-based immunoassays market: Sample movement analysis
- Fig. 21 Blood market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 22 Tissue market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 23 Saliva market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 24 Urine market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 25 MEA biomarker-based immunoassays market: Product outlook key takeaways
- Fig. 26 MEA biomarker-based immunoassays market: Product movement analysis
- Fig. 27 Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 28 Instruments/Analyzers market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 29 Reagent & kits market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 30 Services market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 31 MEA biomarker-based immunoassays market: Biomarker outlook key takeaways
- Fig. 32 MEA biomarker-based immunoassays market: Biomarker movement analysis
- Fig. 33 Safety & toxicity biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 34 Efficacy & pharmacodynamic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 35 Predictive & prognostic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 36 Surrogate/Exploratory biomarkers estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 37 MEA biomarker-based immunoassays market: Biomarker outlook key takeaways
- Fig. 38 MEA biomarker-based immunoassays market: Biomarker movement analysis
- Fig. 39 Cancer market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 40 Cardiovascular diseases market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 41 Neurological diseases market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 42 Immunological diseases estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 43 Others market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 44 MEA biomarker-based immunoassays market: End-use outlook key takeaways
- Fig. 45 MEA biomarker-based immunoassays market: End-use movement analysis
- Fig. 46 Hospitals and clinics market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 47 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 48 Research & academic institutes market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 49 Others estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 50 Biomarker-based immunoassays market: Regional outlook and key takeaways
- Fig. 51 Regional outlook, 2024 & 2030
- Fig. 52 Middle East & Africa
- Fig. 53 MEA market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 54 South Africa key country dynamics
- Fig. 55 South Africa market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 56 Saudi Arabia key country dynamics
- Fig. 57 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 58 UAE key country dynamics
- Fig. 59 UAE market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 60 Kuwait key country dynamics
- Fig. 61 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 62 Market differentiators
- Fig. 63 Key company market share analysis, 2024
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.